Knight Therapeutics Inc T.GUD

Alternate Symbol(s): KHTRF

Healthcare Biotechnology

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.

TSX:GUD - Post by User

Knight Therapeutics Inc

Bullboard Posts

Comment by Snowballgrowthon May 02, 2020 2:36pm

176 Views

Post# 30979652

RE:RE:RE:RE:RE:RE:RE:RE:RE:Remdesivir get approved for emergency use for Covid-19

MUGMODs wrote: As I think about your last comment - that does make sense.
He can get growth out of other people's garbage.
That's what he does.

The probability is high in what you are saying.

Thanks Snowball ... for bringing us back to earth.

Well Mugmod, I appreciate your ideas and I also hope they could get new big drugs. I'm a shareholder too. I just think they work hard to get mostly products with 10-15 M$ sales. It takes a bit more time but it is a very lucrative strategy.

I hope the Brazilian authorities will give us some feedback soon! I can't believe we will wait 5 months for the first step !!

Bullboard Posts

Global Tungsten Market and Supply Security